| 利妥昔单抗在淋巴瘤维持治疗中的新进展 |
| |
| 引用本文： | 毕锡文,陈廷超,姜文奇. 利妥昔单抗在淋巴瘤维持治疗中的新进展[J]. 中国肿瘤临床, 2014, 41(24): 1612-1615. DOI: 10.3969/j.issn.1000-8179.20141313 |
| |
| 作者姓名： | 毕锡文 陈廷超 姜文奇 |
| |
| 作者单位： | ①.中山大学肿瘤防治中心内科（广州市510060） |
| |
| 基金项目： | 深圳市战略性新兴产业发展专项资金JCYJ20120613113228732 |
| |
| 摘 要： | 利妥昔单抗是第一个被批准用于淋巴瘤治疗的单克隆抗体。在弥漫大B细胞性淋巴瘤、滤泡淋巴瘤等B细胞非霍奇金淋巴瘤中取得了显著疗效。对于诱导治疗获得缓解后的滤泡淋巴瘤，利妥昔单抗维持治疗可进一步改善患者预后，为治疗指南所推荐。随着淋巴瘤治疗方案的不断改进，如何更好地把握维持治疗的适应症并进一步优化现有的治疗策略，成为研究的热点。本文通过总结分析近年来的相关文献，对利妥昔单抗用于淋巴瘤维持治疗的最新进展进行综述。
|
| 关 键 词： | 利妥昔单抗 恶性淋巴瘤 维持治疗 |
| 收稿时间： | 2014-08-04 |
Advances in lymphoma maintenance therapy with rituximab |
| |
| Affiliation: | ①.Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China②.Roche Pharmaceuticals, Inc., Shanghai 201203, China |
| |
| Abstract: | Rituximab is the first monoclonal antibody that has been approved for the treatment of lymphoma. Rituximab has shown significant efficacy in the treatment of B-cell non-Hodgkin's lymphomas, such as diffuse large B-cell and follicular lymphomas. Maintenance therapy with rituximab has further improved the prognosis in patients with follicular lymphoma. These patients responded to induction treatment. This antibody treatment has been recommended in treatment guidelines. The treatment strategy for lymphoma has continuously improved. Recent studies focused on how to improve the definition of the indication for maintenance therapy and how to optimize the current maintenance regimens. In this review, we summarized the main studies and the most recent advances on rituximab maintenance therapy in patients with lymphoma. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
